1-3 of 3
Han Ding
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Clinical Trials & Observations
Jeffrey A. Zonder, Ann F. Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar, Anil K. Singhal
Journal: Blood
Blood (2012) 120 (3): 552–559.
https://doi.org/10.1182/blood-2011-06-360552
Published: 2012
Journal Articles

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

Lauri Neyer, PhD, Han Ding, Doreen Chen, James P Sheridan, PhD, Audie Rice, PhD, Balaji Balasa, PhD, Steve Keller, PhD, Yuni Fang, PhD, Angie Albano, Ninian Tran, Vivian Zhao, Daniel EH Afar, PhD
Journal: Blood
Blood (2010) 116 (21): 4070.
https://doi.org/10.1182/blood.V116.21.4070.4070
Published: 2010
Journal Articles

A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P- and L-Selectin

Karen R. Snapp, Han Ding, Kristin Atkins, Roger Warnke, Francis W. Luscinskas, Geoffrey S. Kansas
Journal: Blood
Blood (1998) 91 (1): 154–164.
https://doi.org/10.1182/blood.V91.1.154
Published: 1998